Jonathan P S Knisely Selected Research

Jonathan P S Knisely Research Topics

Disease

25	Neoplasms (Cancer) 06/2023 - 11/2002
17	Brain Neoplasms (Brain Tumor) 04/2024 - 01/2004
13	Meningioma (Meningiomas) 04/2024 - 05/2010
6	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2007
4	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 11/2004
4	Glioma (Gliomas) 01/2023 - 11/2002
3	Adenocarcinoma 12/2015 - 06/2003
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2021
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2018 - 05/2008
2	Melanoma (Melanoma, Malignant) 08/2012 - 01/2007
2	Hypoxia (Hypoxemia) 11/2006 - 11/2002
2	Esophageal Neoplasms (Esophageal Cancer) 03/2006 - 06/2003
1	Central Nervous System Neoplasms 07/2022
1	Astrocytoma (Pilocytic Astrocytoma) 01/2022
1	Oligodendroglioma 01/2022
1	Acoustic Neuroma (Acoustic Neurinoma) 12/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Cardiotoxicity 01/2021
1	Vascular Neoplasms (Neoplasms, Vascular) 01/2021
1	Margins of Excision 12/2015
1	Hemorrhage 12/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2015
1	Anorexia 12/2015
1	Pituitary Neoplasms (Pituitary Adenoma) 07/2014
1	Leukoencephalopathies 05/2012
1	Glomus Jugulare Tumor 12/2010
1	Gallbladder Neoplasms (Gallbladder Cancer) 09/2008
1	Brain Injuries (Brain Injury) 04/2006
1	Inflammation (Inflammations) 04/2006
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 06/2003
1	Hyperthermia 11/2002

Drug/Important Bio-Agent (IBA)

4	Somatostatin Receptors (Somatostatin Receptor)IBA 04/2024 - 10/2020
4	gallium Ga 68 dotatateIBA 10/2023 - 10/2020
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 10/2020
2	GalliumIBA 04/2024 - 01/2022
2	RadiumIBA 01/2022 - 12/2020
2	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2021
2	AntigensIBA 01/2019 - 12/2015
2	Thalidomide (Thalomid)FDA Link 05/2008 - 05/2008
2	Oxygen (Dioxygen)IBA 11/2006 - 11/2002
1	Biomarkers (Surrogate Marker)IBA 03/2024
1	LigandsIBA 10/2023
1	Cesium-131IBA 06/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	cyclo(Arg-Pro) (CI 4)IBA 01/2022
1	AcidsIBA 01/2022
1	Lomustine (CCNU)FDA Link 01/2022
1	Procarbazine (Matulane)FDA Link 01/2022
1	Vincristine (Oncovin)FDA LinkGeneric 01/2022
1	somatostatin receptor 2IBA 01/2021
1	Estrogen ReceptorsIBA 01/2021
1	BRCA1 ProteinIBA 01/2021
1	mesoglycanIBA 12/2020
1	Indium-111IBA 10/2020
1	Octreotide (Sandostatin)FDA LinkGeneric 10/2020
1	Capecitabine (Xeloda)FDA Link 12/2015
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 07/2014
1	Growth Hormone (Somatotropin)IBA 07/2014
1	Adrenocorticotropic Hormone (ACTH)FDA Link 07/2014
1	ProlactinIBA 07/2014
1	Phenobarbital (Luminal)FDA Link 05/2013
1	IpilimumabIBA 08/2012
1	CatecholaminesIBA 12/2010
1	Indicators and Reagents (Reagents)IBA 11/2006
1	carbamylated erythropoietinIBA 04/2006
1	CytokinesIBA 04/2006
1	Erythropoietin FDA Link 04/2006
1	prinomastat (Ag3340)IBA 03/2006
1	Metalloproteases (Metalloproteinases)IBA 03/2006
1	Matrix Metalloproteinase InhibitorsIBA 03/2006
1	Hemoglobins (Hemoglobin)IBA 11/2004
1	Fluorouracil (Carac)FDA LinkGeneric 06/2003
1	Cisplatin (Platino)FDA LinkGeneric 06/2003
1	Antineoplastic Agents (Antineoplastics)IBA 11/2002

Therapy/Procedure

24	Radiotherapy 10/2023 - 06/2003
9	Therapeutics 10/2023 - 11/2002
5	Drug Therapy (Chemotherapy) 01/2022 - 11/2002
4	Immunotherapy 01/2023 - 01/2018
2	Brachytherapy 06/2023 - 07/2022
2	Re-Irradiation 01/2023 - 01/2023
2	Particle Accelerators 01/2023 - 12/2021
2	Combined Modality Therapy 01/2022 - 03/2006
2	Aftercare (After-Treatment) 01/2021 - 12/2010
2	Precision Medicine 01/2018 - 01/2018
2	Cranial Irradiation 01/2018 - 05/2008
2	Chemoradiotherapy 12/2015 - 06/2003
1	Craniotomy 01/2022
1	Contraindications 01/2022
1	Adjuvant Chemoradiotherapy 12/2015
1	Conformal Radiotherapy 05/2010
1	Neoadjuvant Therapy 06/2003